Europe and the US: A connective tissue across biotech

The latest article published in Healthcare Today explores how the rules for expanding into Europe are changing for US biotech companies.

In the interview, Kirsten Detrick, US Representative for the Basel Area Life Sciences Supercluster and Adjunct Professor of Business Administration at the Tuck School of Business, explains why success increasingly depends on planning for Europe early rather than treating it as a single market.

As commercial pressures grow and investment becomes more disciplined, companies need to rethink their expansion strategies. Building a coordinated European presence that integrates commercial, market access and R&D functions from the outset can help organizations navigate Europe’s diverse healthcare systems, prioritize the right launch markets and scale more effectively.

The interview also highlights why the Basel Area Life Sciences Supercluster is well positioned to support that approach. The region brings together an exceptional concentration of life sciences talent, global pharmaceutical companies, emerging biotechs and leading research institutions. This close collaboration enables companies to move more efficiently from discovery to commercialization.

Combined with its tri-national location and high quality of life, the Basel Area offers companies a strong foundation for building a long-term European presence.

Ultimately, the interview reinforces a timeless principle: while markets and policies evolve, scientific progress continues to be driven by talent, collaboration and the free exchange of ideas.